Aug 2026· Frontiers in Immunology· Vol 17· 0 citations· 161 references
Medicine
TL;DR
The transition from immune - to a mutational-perspective, provides a foundational framework to optimize diagnostic and therapeutic strategies for precision medicine in SAVI patients.
Abstract
Type I interferonopathies (TI-IFN) represent a heterogeneous group of autoinflammatory disorders characterized by upregulated type I interferon (IFN) signaling. Among them, STING-associated vasculopathy with onset in infancy (SAVI) is a rare, severe autoinflammatory disease caused by gain-of-function mutations in the STING1 gene. Mechanistically, these mutations lead to a constitutive activation of the STING protein, resulting in excessive type I interferon production, which drives chronic inflammation and damage to various organs, primarily as cutaneous vasculopathy and progressive interstitial lung disease (ILD). Emerging clinical data indicate that current therapeutic options – including Janus kinase inhibitors (JAKi), biological agents as anifrolumab and solid organ transplantation – for SAVI face limited and often inconsistent long-term efficacy, highlighting a significant unmet need. Consistently, preclinical models highlight that SAVI pathogenesis is not only driven by the interferon storm, but relies also on non-canonical IFN-independent cellular pathways across distinct hematopoietic and non-hematopoietic compartments. This review provides a comprehensive overview of SAVI pathogenesis, from mutational mechanisms and comparative phenotypes to the clinical challenges of advanced interventions. Finally, we discuss future therapeutic prospects and clinical implications, exploring next-generation frontiers such as patient-derived induced pluripotent stem cell (iPSCs) models, hematopoietic stem cell transplantation (allo-HSCT) and gene editing (GE) technologies. The transition from immune - to a mutational-perspective, provides a foundational framework to optimize diagnostic and therapeutic strategies for precision medicine in SAVI patients.
Type I interferonopathies are a heterogeneous group of monogenic autoinflammatory disorders characterized by dysregulated type I interferon (IFN-I) signaling due to pathogenic variants that affect nucleic acid sensing, processing, or downstream signaling pathways. Mutations in genes including TREX1, RNASEH2A/B/C, SAMHD...
Nida Gürbüz, S. Ismayilova, G. Ahmadova et al.· Journal of Visualized Experi...· 0 citations
Autoinflammatory disorders arise from dysregulated innate immunity, most commonly involving inflammasome activation and excessive interleukin-1 (IL-1) signaling. Although rare, these conditions are increasingly recognized across age groups as genetic testing expands and phenotypic classification improves.
Therapeutic...
A. Diamantopoulos· Journal of Human Immunity· 0 citations
Type 2 inflammatory diseases are often grouped together as a single immunological entity, driven by shared cytokines and overlapping pathways. This framework has led to the development of biologic therapies targeting upstream epithelial-derived “alarmins”, including thymic stromal lymphopoietin (TSLP), interleukin (IL)...
Y. Tal, Limor Rubin, A. Munitz et al.· Frontiers in Immunology· 0 citations
ABSTRACT Introduction Still’s disease is a systemic inflammatory disorder characterized by a complex cytokine network involving interleukin (IL)-1, IL‑6, IL‑18 and interferon (IFN)-γ. Although IL‑1 and IL‑6 inhibitors represent the cornerstone of current targeted therapy, a subset of patients remains refractory or deve...
P. Ruscitti, F. Ursini, R. Giacomelli et al.· Expert Opinion on Pharmacoth...· 0 citations
Impaired interferon (IFN) production plays a key role in the pathogenesis of a wide range of autoimmune diseases (AIDs), such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), dermatomyositis, and others. This review examines both the physiological functions of IFNs under normal conditions (antiviral defe...
T. Ospelnikova, A. D. Shitova, O. N. Egorova et al.· Annals of the Russian academ...· 0 citations
Experimental models support distinct LN‑promoting roles of type I, II, and III IFNs, suggesting that targeting upstream triggers of IFN production, in addition to directly inhibiting IFN signaling, may represent promising therapeutic strategies.
M. Meineck, Janine Riepl, P. Claßen et al.· Autoimmunity· 0 citations
Enforcing physics-based constraints prevents AI models from generating unreliable predictions for complex nonlinear systems in weather, climate, and turbulent flows.
MIT News · Artificial Intelligence· news.mit.eduNov 18, 2026